The US Department of Health and Human Services (HHS) has outlined a new strategy aimed at reinforcing the country’s position in pharmaceutical research as competition from China intensifies. Through an initiative called Operation Trailblazer, HHS plans to introduce measures designed to accelerate drug development, reduce delays in clinical studies, expand participation in research programmes, and strengthen domestic capabilities. The move comes amid concerns that China has gained significant momentum in transforming scientific discoveries into medicines, with its share of global clinical trial starts increasing from 1% in 2009 to 32% in 2025. The programme is intended to restore the competitiveness of US clinical trials and encourage more research activity to remain within the country.
According to HHS, an increasing proportion of early-stage clinical research has shifted overseas in recent years. In response, the department said it is taking action to make the United States a preferred location for medical discovery and clinical development. Responsibility for implementing the initiative will be shared among several HHS agencies, including the FDA, NIH, and the Office of the National Coordinator for Health Information Technology (ONC). The FDA plans to establish a pilot programme intended to streamline first-in-human studies and introduce measures that could shorten early-stage trial timelines by six to 12 months. The agency is also pursuing previously announced efforts that would allow certain medicines to be approved based on one pivotal trial rather than two.
The NIH will expand support for clinical research involving artificial intelligence, human cell-based models, and real-world data while creating practical resources for drug developers. Meanwhile, the ONC will examine approaches to improve connections between patients and clinical research opportunities through electronic health records. HHS also intends to create a network of qualified research institutions that brings together academic organisations, healthcare systems, regulators, and industry partners to accelerate the evaluation of promising therapies. The department stated: “For this to be a success, the entire US research enterprise will need to do its part to streamline their processes.” It added: “HHS will continue working with industry, academic medical centres, contract research organisations, patient groups, healthcare providers, and other partners to identify barriers to clinical research and remove unnecessary obstacles that slow innovation.” Similar initiatives have recently emerged in the European Union, the United Kingdom, and Japan, creating a more competitive global landscape for US Clinical Trials and future study launches.
